A $3.15bn deal follows a December 2024 option agreement.
ApexOnco Front Page
Recent articles
The groups spend big on Terns and Arcellx.
Rinzimetostat efficacy wanes further as the company moves into phase 3.
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
The group wants to improve on its own Welireg in a new phase 3 trial.
Replimune gets a second chance, while Sarclisa could go subcutaneous.
After a delay, the Alpha-3 study faces an April futility analysis.
Early data are coming with the KRAS G12D degrader ARV-806.
